Abstract

Major Ongoing Stroke Trials

Highlights

  • The development of persistent depressive symptoms is a severe and frequent complication of ischemic stroke

  • Summary: Up to 40% of acute stroke patients on hospital admission are already taking antihypertensive therapy, and most will e41

  • Blood pressure, modified Rankin Scale score, Barthel Index and National Institutes of Health Stroke Score will be repeated at 2 weeks by an observer blinded to the randomized group

Read more

Summary

Introduction

The development of persistent depressive symptoms is a severe and frequent complication of ischemic stroke (i.e., poststroke depression, PSD). The MASH-II study is a prospective randomized, placebocontrolled, international multicenter trial to determine whether magnesium reduces the frequency of poor outcome (death or dependence) in patients admitted within 4 days after aneurysmal subarachnoid hemorrhage. E-mail Philip.bath@nottingham.ac.uk Location: University of Nottingham, Nottingham, UK Number of Centers: Those centers that have organized a positive or negative randomized controlled trial in acute stroke or stroke rehabilitation Sponsor: The Stroke Association (UK) Dates of Study: October 2004 (continuing)

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.